explore -WSS

explore

author：knowledge 2025-09-27 12:57:47 - browse：4281

Verve Therapeutics CEO Sekar Kathiresan Verve

SAN FRANCISCO — The promise of genome editing has given rise to potentially curative medicines for rare, life-threatening diseases that generally affect small numbers of patients. But since Verve Therapeutics was founded in 2018, it’s had a wider aperture: using the molecular tools of genome editing to go after the most common cause of death in the world.

The plan, according to Verve CEO Sekar Kathiresan, is to edit out heart attacks for the millions of people at risk for severe cardiovascular disease. It’s a goal that’s more than a little audacious. There’s just one approved genome editing medicine, a treatment for sickle cell disease, and it only passed Food and Drug Administration review last month. Base editing, the CRISPR successor Verve uses to conduct its molecular surgery, is only a few years old.

“When we started, there were so many things that we were kind of going against the grain on,” Kathiresan told STAT at the J.P. Morgan Healthcare Conference in San Francisco this week. “In 2018, it was all about platforms, not about specific diseases and products, or taking this kind of idea for a large indication as opposed to cancer or rare disease. But we’ve always been motivated by a deep conviction in one simple research insight, which is that if your blood cholesterol is really low, lifelong, it is very hard to get a heart attack.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Yancopoulos of Regeneron works to expand Dupixent success

hotspot

knowledge

WSS

Medicare Advantage insurers pressure Biden for bigger payments

A single drug, study failures leave Anavex with nothing but cash

A single drug, study failures leave Anavex with nothing but cash

The biotech scorecard for Q1: 17 stock

UCB departs biotech trade group BIO

Readout LOUD podcast, live from the STAT Breakthrough Summit East

entertainment

explore

Wikipedia

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

JPM: CVS says Medicare Advantage patients are impacting profits

Trump demands the U.S. pay no more for drugs than other countries … again

Videos point to link between seizures and unexplained toddler deaths

As demand for Covid shots wanes, Moderna seeks its next success

Diabetes management: Digital health tools fall short, study says

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Morgan Health, with ambitious aims, wants you to know it’s still here

Sports medicine is finally prioritizing gender equality

Why psychiatrists like me stop taking insurance

hotspot

Antibiotic resistance and the global rise in human conflict

Texas board proposes rules on abortion law emergency exemption

With Wegovy coverage, Medicare patients may face high costs

CRISPR technology availability, affordability needs to be expanded

Feng Zhang, Grail founder join forces on new gene editing startup

U.K. sequencing study surfaces new findings about tumor DNA

explore

hotspot

knowledge

hotspot